Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial

Table 2 General traits and physical activity levels of overweight/obese patients with non-alcoholic fatty liver disease (NAFLD)

Variables			Nanocurcumin (n = 42) n(%) or Mean(SD)	Placebo (n = 42) n(%) or Mean(SD)	P-value
Age (yrs)			41.8(5.6)	42.5(6.2)	0.2^*
Gender	male		23(54.8)	23(54.8)	1.0^**
Gender	female		19(45.2)	19(45.2)	1.0^**
Height (cm)			167.8(9.8)	167.7(9.0)	0.8^*
Marriage status	single		5(11.9)	7(16.7)	0.5^**
Marriage status	married		37(88.1)	35(83.3)	0.5^**
Job status	employee, free job/retired		31(73.8)	25(59.5)	0.1^**
Job status	housewife, unemployed		11(26.2)	17(40.5)	0.1^**
Education level	up to associate degree		21(50)	20(47.6)	0.8^**
Education level	Bachelor and higher		21(50)	22(52.4)	0.8^**
Economic level	Low (≤3 living items)		0(0)	0(0)	0.8^**
	moderate (4–6 living items)		19(45.2)	18(42.9)
	High (≥7 living items)		23(54.8)	24(57.1)
Physical activity level (Baseline)	low (< 600 MET-minutes/week)		31(73.8)	28(66.7)	0.4^**
	Moderate (600 to < 1500 MET-minutes/week)		11(26.2)	14(33.3)
	High (≥ 1500 MET-minutes/week)		0(0)	0(0)
Physical activity level (After 3 months)	low (< 600 MET-minutes/week)		27(64.3)	26(61.9)	0.8^$
	Moderate (600 to < 1500 MET-minutes/week)		15(35.7)	16(38.1)
	High (≥ 1500 MET-minutes/week)		0(0)	0(0)
Fatty liver (Baseline)	No		0(0)	0(0)	0.5^**
	Yes	Mild	35(83.3)	37(88.1)
		Moderate	7(16.7)	5(11.9)
		Severe	0(0)	0(0)
Fatty liver (After 3 months)	No		20(47.6)	5(11.9)	< 0.001^**
	Yes	Mild	21(50.0)	33(78.6)
		Moderate	1(2.4)	4(9.5)
		Severe	0(0)	0(0)

ISSN: 1743-7075